JP2011067180A - Food and drink composition, and medicinal composition - Google Patents
Food and drink composition, and medicinal composition Download PDFInfo
- Publication number
- JP2011067180A JP2011067180A JP2009223187A JP2009223187A JP2011067180A JP 2011067180 A JP2011067180 A JP 2011067180A JP 2009223187 A JP2009223187 A JP 2009223187A JP 2009223187 A JP2009223187 A JP 2009223187A JP 2011067180 A JP2011067180 A JP 2011067180A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- minutes
- methanol
- furocoumarins
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 235000013305 food Nutrition 0.000 title abstract description 10
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 claims abstract description 80
- 229930182470 glycoside Natural products 0.000 claims abstract description 19
- 150000002338 glycosides Chemical class 0.000 claims abstract description 18
- 230000035622 drinking Effects 0.000 claims description 9
- 239000003814 drug Substances 0.000 abstract description 11
- 208000007578 phototoxic dermatitis Diseases 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 9
- 239000002994 raw material Substances 0.000 abstract description 8
- 208000017520 skin disease Diseases 0.000 abstract description 6
- 235000008730 Ficus carica Nutrition 0.000 abstract description 5
- 244000025361 Ficus carica Species 0.000 abstract description 3
- 206010048768 Dermatosis Diseases 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 69
- BGEBZHIAGXMEMV-UHFFFAOYSA-N 5-methoxypsoralen Chemical compound O1C(=O)C=CC2=C1C=C1OC=CC1=C2OC BGEBZHIAGXMEMV-UHFFFAOYSA-N 0.000 description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 28
- 238000000605 extraction Methods 0.000 description 26
- DBMJZOMNXBSRED-UHFFFAOYSA-N Bergamottin Natural products O1C(=O)C=CC2=C1C=C1OC=CC1=C2OCC=C(C)CCC=C(C)C DBMJZOMNXBSRED-UHFFFAOYSA-N 0.000 description 23
- 239000000284 extract Substances 0.000 description 23
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 21
- 229960002045 bergapten Drugs 0.000 description 21
- KGZDKFWCIPZMRK-UHFFFAOYSA-N bergapten Natural products COC1C2=C(Cc3ccoc13)C=CC(=O)O2 KGZDKFWCIPZMRK-UHFFFAOYSA-N 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 229940057324 biore Drugs 0.000 description 16
- 239000004519 grease Substances 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 241000283153 Cetacea Species 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 9
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 9
- 239000000401 methanolic extract Substances 0.000 description 9
- 235000013616 tea Nutrition 0.000 description 9
- 230000009471 action Effects 0.000 description 8
- 244000269722 Thea sinensis Species 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 239000000538 analytical sample Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 241000411851 herbal medicine Species 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- HCGFUIQPSOCUHI-UHFFFAOYSA-N 2-propan-2-yloxyethanol Chemical compound CC(C)OCCO HCGFUIQPSOCUHI-UHFFFAOYSA-N 0.000 description 4
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 4
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- DBMJZOMNXBSRED-OQLLNIDSSA-N bergomottin Chemical compound O1C(=O)C=CC2=C1C=C1OC=CC1=C2OC/C=C(C)/CCC=C(C)C DBMJZOMNXBSRED-OQLLNIDSSA-N 0.000 description 4
- 229930182478 glucoside Natural products 0.000 description 4
- 150000008131 glucosides Chemical class 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- -1 methoxyl group Chemical group 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000218218 Ficus <angiosperm> Species 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000006286 aqueous extract Substances 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002386 leaching Methods 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 2
- 241000218231 Moraceae Species 0.000 description 2
- 206010034972 Photosensitivity reaction Diseases 0.000 description 2
- 244000117054 Rungia klossii Species 0.000 description 2
- 235000002492 Rungia klossii Nutrition 0.000 description 2
- PCWZKQSKUXXDDJ-UHFFFAOYSA-N Xanthotoxin Natural products COCc1c2OC(=O)C=Cc2cc3ccoc13 PCWZKQSKUXXDDJ-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000000752 ionisation method Methods 0.000 description 2
- 229960004469 methoxsalen Drugs 0.000 description 2
- SQBBOVROCFXYBN-UHFFFAOYSA-N methoxypsoralen Natural products C1=C2OC(=O)C(OC)=CC2=CC2=C1OC=C2 SQBBOVROCFXYBN-UHFFFAOYSA-N 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 231100000018 phototoxicity Toxicity 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 241001341314 Artena Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 241000546188 Hypericum Species 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- RNKZFOIQKCQOAQ-UHFFFAOYSA-N Isopimpinellin Natural products COC1CC(=O)Oc2c(OC)c3occc3cc12 RNKZFOIQKCQOAQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241001446509 Psoralea Species 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N benzofuran Natural products C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 150000001893 coumarin derivatives Chemical class 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000019990 fruit wine Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- DFMAXQKDIGCMTL-UHFFFAOYSA-N isopimpinellin Chemical compound O1C(=O)C=CC2=C1C(OC)=C1OC=CC1=C2OC DFMAXQKDIGCMTL-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000002165 photosensitisation Effects 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、イチジクを原料とする飲食用組成物及び薬用組成物に関するものである。 The present invention relates to a edible composition and a medicinal composition made from figs.
イチジクは、アラビア南部を原産地とするクワ科の植物であり、単に飲食用だけでなく、古くから薬用植物としても利用されている(非特許文献1参照)。また近年の研究では、イチジクは、血糖値の降下作用、降血圧作用、抗がん作用、及び免疫力を高める作用等を有することも明らかとなっている(非特許文献2参照)。 Figs are mulberry plants originating in southern Arabia and have been used not only for eating and drinking but also for medicinal plants for a long time (see Non-Patent Document 1). In recent studies, it has also been clarified that figs have a blood glucose level lowering action, a blood pressure lowering action, an anticancer action, an action to enhance immunity, and the like (see Non-Patent Document 2).
飲食用や薬用としても有用なイチジクではあるが、成分としてフロクマリン類を含んでいる。このフロクマリン類はそれを摂取あるいは皮膚に付着することによって、紅斑、色素沈着、びらんの症状を呈する光毒性接触皮膚炎を発症したり、あるいは薬物の副作用が増大して健康被害を招く場合がある。これは、フロクマリン類が、光増感剤として作用する、あるいはある種の薬物代謝酵素の働きを阻害することが原因であると考えられている。実際に、イチジク葉を揉み出した水で行水を行って、上記症状を伴う光毒性接触皮膚炎を発症した例が報告されている(谷 守、「化学物質による皮膚障害 36 植物による光毒性接触皮膚炎」、医薬ジャーナル38巻、2002年、p2398−2405)。 Although it is a fig useful for eating and drinking and medicinal purposes, it contains furocoumarins as an ingredient. These furocoumarins may cause phototoxic contact dermatitis that causes symptoms of erythema, pigmentation, and erosion by ingesting or adhering to the skin, or side effects of the drug may increase and cause health damage. . This is thought to be due to the fact that furocoumarins act as photosensitizers or inhibit the action of certain drug-metabolizing enzymes. In fact, there have been reports of cases in which phototoxic contact dermatitis with the above-mentioned symptoms was caused by running water with water that squeezed fig leaves (Tamoru Tani, “Skin damage caused by chemicals 36 Phototoxicity caused by plants” Contact Dermatitis ", Med. Journal 38, 2002, p 2398-2405).
従って本発明の目的は、光毒性接触皮膚炎等の光による皮膚疾患の発症や、薬物の副作用を増大させる虞のない、イチジクを原料とする飲食用組成物及び薬用組成物を提供することにある。 Accordingly, an object of the present invention is to provide a food-drinking composition and a medicinal composition using fig as a raw material, without causing the onset of skin diseases caused by light such as phototoxic contact dermatitis and the side effects of drugs. is there.
上記目的を達成するための本発明の飲食用組成物及び薬用組成物に係る第1特徴構成は、フロクマリン類及びフロクマリン関連配糖体を含まないイチジク品種を原料とする点にある。 In order to achieve the above object, the first feature of the food and beverage composition and medicinal composition of the present invention is that the raw material is a fig variety that does not contain furocoumarins and furocoumarin-related glycosides.
〔作用及び効果〕
本発明の飲食用組成物及び薬用組成物は、フロクマリン類と、加水分解されてフロクマリン類が生成される可能性のあるフロクマリン関連配糖体とを含有しないイチジク品種を用いて構成される。このため、本発明の飲食用組成物及び薬用組成物を摂取したとしても、光毒性接触皮膚炎等の光による皮膚疾患の発症や、薬物の副作用を増大させる等の健康被害をもたらす虞がない。
[Action and effect]
The food-drinking composition and medicinal composition of the present invention are configured using fig varieties that do not contain furocoumarins and furocoumarin-related glycosides that can be hydrolyzed to produce furocoumarins. For this reason, even if the eating and drinking composition and the medicinal composition of the present invention are ingested, there is no risk of causing health damage such as the onset of skin diseases caused by light such as phototoxic contact dermatitis and the increase of drug side effects. .
本発明の飲食用組成物及び薬用組成物に係る第2特徴構成は、前記イチジク品種が、グリース・ド・タラスコン(Grise de Tarascon)又はビオレ・ドーフィン(Violette Dauphine)である点にある。 The 2nd characteristic structure which concerns on the food-drinks composition and medicinal composition of this invention exists in the point whose said fig varieties are a grease de tarascon (Grise de Talascon) or a biore dauphin (Violet Dauphine).
〔作用及び効果〕
後述する実施例に示されるように、グリース・ド・タラスコン、及びビオレ・ドーフィンの2品種は、少なくともフロクマリン類のプソラレン及びベルガプテン、並びにフロクマリン関連配糖体のイソプソラル酸グルコシド(以下、IPGと称する)及びイソプソラル酸グルコシドにメトキシル基が一つ付加された化合物(以下、mIPGと称する)を含まないことが本発明者らの鋭意研究によって確認されている。
尚、IPG及びmIPGのそれぞれが加水分解されることによって、プソラレン及びベルガプテンが生成されると考えられている。
即ち、グリース・ド・タラスコン、及びビオレ・ドーフィンの2品種においては、プソラレン及びベルガプテンが含まれず、さらにIPG及びmIPGを含まないためプソラレン及びベルガプテンが生成される虞もない。
従って、本発明の飲食用組成物及び薬用組成物は、特にプソラレンやベルガプテン等が関与するとされる光毒性接触皮膚炎等の光による皮膚疾患を発症させる虞がなく、また薬物の代謝・吸収への影響も避けられるため、安心して摂取することができる。
[Action and effect]
As shown in Examples described later, the two varieties of Grease de Tarascon and Biore Dauphin are at least psoralen and bergapten of furocoumarins, and isopsolar acid glucoside (hereinafter referred to as IPG) of furocoumarin-related glycosides. Further, it has been confirmed by the present inventors that the compound does not contain a compound in which one methoxyl group is added to isopsolar acid glucoside (hereinafter referred to as mIPG).
In addition, it is thought that psoralen and bergapten are produced | generated by each hydrolyzing IPG and mIPG.
That is, the two types of grease de tarascon and biore dofin do not contain psoralen and bergapten, and since IPG and mIPG are not contained, there is no possibility that psoralen and bergapten are produced.
Therefore, the composition for food and drink and the medicinal composition of the present invention have no risk of developing a skin disease caused by light such as phototoxic contact dermatitis, which is particularly associated with psoralen, bergapten, etc. Can also be taken with peace of mind.
本明細書中において使用される用語について説明する。
(イチジク)
本発明に適用されるイチジク(Ficus carica L.)とは、アラビア南部を原産地とするクワ科の植物である。
Terms used in this specification will be described.
(FIG)
Fig (Ficus carica L.) applied to the present invention is a plant of the mulberry family that originates in southern Arabia.
本発明に適用可能なイチジクの品種としては、フロクマリン類及びフロクマリン関連配糖体を含有しないイチジク品種であれば特に限定されるものではないが、例えば、「グリース・ド・タラスコン(Grise de Tarascon)」又は「ビオレ・ドーフィン(Violette Dauphine)」等が挙げられる。 The fig variety applicable to the present invention is not particularly limited as long as it is a fig variety that does not contain furocoumarins and furocoumarin-related glycosides. For example, “Grise de Tarascon” Or “Violet Dauphine”.
尚、本発明における「フロクマリン類及びフロクマリン関連配糖体を含有しないイチジク品種」とは、文字通りこれらの化合物を全く含まない品種だけでなく、これらの化合物をほとんど含まない品種も含まれるものとする。 As used herein, the term “ficus varieties that do not contain furocoumarins and furocoumarin-related glycosides” literally includes not only varieties that do not contain these compounds at all, but also varieties that hardly contain these compounds. .
フロクマリン類及びフロクマリン関連配糖体を全く含まない品種とは、その果実、葉、茎、根等について所定の溶媒(水、もしくは水とアセトンの混合液、もしくはメタノール(0.1%程度の塩酸を添加する場合もある))を用いて抽出して分析操作を行っても、これらの化合物が検出されなかった品種を意味する。 The varieties that do not contain furocoumarins and furocoumarin-related glycosides are a specified solvent (water or a mixture of water and acetone, or methanol (about 0.1% hydrochloric acid) for its fruits, leaves, stems, roots, etc. ) Means a variety in which these compounds were not detected even after extraction and analysis.
フロクマリン類及びフロクマリン関連配糖体をほとんど含まない品種とは、乾物1g当たりのフロクマリン類の重量(mg)が0.1mg以下であって、フロクマリン関連配糖体の重量(mg)が0.1mg以下である品種を意味する。 The varieties that hardly contain furocoumarins and furocoumarin-related glycosides have a weight (mg) of furocoumarins per gram of dry matter of 0.1 mg or less, and the weight (mg) of furocoumarin-related glycosides of 0.1 mg. It means the following varieties.
(フロクマリン類)
フロクマリン(furocoumarine)類とは、フラン環が縮合したクマリン誘導体の総称である。フロクマリン類は、セリ科、ミカン科、マメ科、クワ科、キク科、オトギリソウ科等の植物に多く含まれる。フロクマリン類に属する化合物としては、例えば、プソラレン(psoralen)、ベルガプテン(bergapten)、キサントトキシン(xanthotoxin)、イソピンピネリン(isopimpinellin)、ベルガモチン(bergamottin)、ジヒドロキシベルガモチン(dihydroxybergamottin)等が挙げられる。
(Furocoumarins)
Furocoumarins is a general term for coumarin derivatives condensed with a furan ring. Furocoumarins are abundant in plants such as celery family, citrus family, legume family, mulberry family, asteraceae family, and hypericum family. Examples of the compounds belonging to furocoumarins include psoralen, bergapten, xanthotoxin, isopimpinellin, bergamotin, dihydroxybergamotine, etc.
フロクマリン類は、抗菌作用や、植物を食べる昆虫の消化を妨げる作用を有しており、植物の防御機構を担う物質の一つと考えられているが、後述するように、フロクマリン類を摂取又は接触したヒトにおいていくつかの健康被害をもたらす場合がある。 Furocoumarins have antibacterial action and action to prevent digestion of insects that eat plants, and are considered to be one of the substances responsible for the defense mechanism of plants. May cause some health hazards in the affected human.
例えば、プソラレンが皮膚に付着した状態で日光(紫外線)を浴びると、日焼けの度合いが強くなったり、シミが生じたり、さらには光毒性接触皮膚炎を発症させる場合がある(谷 守著、「化学物質による皮膚障害 36 植物による光毒性接触皮膚炎」、医薬ジャーナル、2002年、38、p2398−2405)。これは、フロクマリン類は、自らが光を吸収して得たエネルギーを他の物質に渡すことで、反応や発酵のプロセスを促進させる、いわゆる光増感作用を有するためであると考えられている。 For example, exposure to sunlight (ultraviolet rays) with psoralen attached to the skin may increase the degree of sunburn, cause spots, and even phototoxic contact dermatitis (Mr. Tani, “ Skin damage caused by chemical substances 36 Phototoxic contact dermatitis caused by plants ", Medicinal Journal, 2002, 38, p2398-2405). This is thought to be because furocoumarins have a so-called photosensitizing action that promotes the reaction and fermentation process by passing energy obtained by absorbing light to other substances. .
また、ベルガモチンやジヒドロキシベルガモチンと共にある種の薬物を摂取したとき、その薬物の副作用を増大させてしまう場合がある。これは、ベルガモチンやジヒドロキシベルガモチンが、小腸上皮細胞に存在する薬物代謝酵素(CYP3A4)の機能を阻害するためであると考えられている。CYP3A4には、ある種の薬物をある程度代謝して不活性化することによって循環血液中に移行する薬物量を少なくする働きがある。そのため、ベルガモチンやジヒドロキシベルガモチンによってCYP3A4の機能が阻害されると、CYP3A4による薬物の不活性化が妨げられて、循環血液中に移行する薬物量が多くなり、結果として薬物が効き過ぎて副作用を増大させてしまうこととなる。 Further, when a certain drug is taken together with bergamotine or dihydroxybergamotin, side effects of the drug may be increased. This is considered to be because bergamotine and dihydroxybergamotin inhibit the function of a drug-metabolizing enzyme (CYP3A4) present in small intestinal epithelial cells. CYP3A4 has a function of reducing the amount of a drug transferred to the circulating blood by metabolizing a certain drug to some extent and inactivating it. Therefore, when the function of CYP3A4 is inhibited by bergamotin or dihydroxybergamotin, the inactivation of the drug by CYP3A4 is prevented, resulting in an increase in the amount of drug that moves into the circulating blood, resulting in the drug being too effective and causing side effects It will increase.
尚、フロクマリン類を経口摂取した場合の許容量については、必ずしも全てのフロクマリン類について明確な知見が得られてはいないが、ベルガプテン及びキサントトキシンのヒトに対する許容量を調べた研究によると、一度に15mg以上摂取して紫外線を浴びると光毒症を発症する虞があり、10mg以下であれば発症する可能性は低いとの報告がある(Schlatter,J.,Zimmerli,B.,Dick,R,Panizzon,R.and Schlatter,Ch.、「Dietary Intake and Risk Assessment of Phototoxic Furocoumarins in Humans」、Food Chem.Toxicology、1991、29(8)、p523−530)。 In addition, regarding tolerable doses when orally ingesting furocoumarins, it is not always clear about all furocoumarins, but according to a study that examined the tolerable amount of bergapten and xanthotoxin in humans, There is a possibility that phototoxicity may occur if 15 mg or more is ingested and exposed to ultraviolet rays, and if it is 10 mg or less, the possibility of developing is low (Schlatter, J., Zimmerli, B., Dick, R). , Panizzon, R. and Schlatter, Ch., “Dietary Intake and Risk Assessment of Phototoxicology in Humans”, Food Chem. Toxicology, 1991, 29, 295, 295, pp. ).
(フロクマリン関連配糖体)
本発明におけるフロクマリン関連配糖体とは、加水分解を受けることでフロクマリン類を生じる物質を意味するものであり、例えば、イソプソラル酸グルコシド(以下、IPGと称する)、及びイソプソラル酸グルコシドにメトキシル基が一つ付加された以下の〔化1〕に示された化合物(以下、mIPGと称する)等が挙げられる(笠島直樹、古武孝仁、塩田澄子、金田幸、「日本生薬学会 第55回年会 長崎2008 講演要旨集 (薬用植物資源の研究 クワ科植物イチジク(Ficus carica)葉部の成分(第1報))」、日本生薬学会、平成20年9月19日・20日、p238)。
(Furocoumarin-related glycosides)
The furocoumarin-related glycoside in the present invention means a substance that generates furocoumarins upon hydrolysis. For example, isopsolar acid glucoside (hereinafter referred to as IPG), and isopsolar acid glucoside has a methoxyl group. The compound shown in the following [Chemical Formula 1] (hereinafter referred to as mIPG) and the like are included (Naoki Kasajima, Takahito Furutake, Sumiko Shioda, Yuuki Kaneda, “The 55th Annual Meeting of the Japanese Biopharmaceutical Society” Abstracts of Nagasaki 2008 (Studies on Medicinal Plant Resources, Components of Leaves of Ficus carica (First Report)), Japan Biopharmaceutical Society, September 19-20, 2008, p238.
尚、IPGは漢方薬素材「補骨脂」の原料になるマメ科植物のオランダヒユ類(Psoralea corylifolia L.)の種子にも含まれており、加水分解されるとプソラレンを生じる(Qiao,C.−F.,Han,Q.−B.,Mo,S.−F.,Song,J.−Z.,Xu,L.−J.,Chen,S.−L.,Yang,D.−J.,Kong,L.−D.,Kung,H.−F.andXu,H.−X.、「Psoralenoside and Isopsoralenoside, Two New Benzofuran Glycosides from Psoralea corylifolia」、Chem.Pharm.Bull、2006、54(5)、p714―716)。また、mIPGが加水分解されると、ベルガプテンを生じると推定される。 IPG is also contained in the seeds of leguminous plants, Psolalea corifolia L., which is a raw material for the Chinese herbal medicine “prosthetic fat” and generates psoralen when hydrolyzed (Qiao, C.-). F., Han, Q.-B., Mo, S.-F., Song, J.-Z., Xu, L.-J., Chen, S.-L., Yang, D.-J. , Kong, L.-D., Kung, H.-F. and Xu, H.-X., “Psoralenoid and Isosoralenoside, Two New Benzofuran Glycosides from Psoralea Coli. P714-716). Moreover, when mIPG is hydrolyzed, it is estimated that bergapten is produced.
〔実施形態〕
本発明は、フロクマリン類及びフロクマリン関連配糖体を含まないイチジク品種(例えば、グリース・ド・タラスコン又はビオレ・ドーフィン等)の果実、葉、茎、根等、あるいはこれらの抽出物を原料とする飲食用組成物及び薬用組成物に関するものである。
Embodiment
The present invention uses, as a raw material, fruits, leaves, stems, roots, etc. of fig varieties (eg, grease de tarascon or biore dofin) that do not contain furocoumarins and furocoumarin-related glycosides, or extracts thereof. The present invention relates to a food and drink composition and a medicinal composition.
(飲食用組成物)
本発明に係る飲食用組成物としては、例えば、茶葉が挙げられる。茶葉は、摘み取った上記イチジク品種の葉に(1)蒸気に通して短時間で加熱して蒸す蒸し工程、(2)茶の葉の表面の水分を取り除きながら冷やす冷却工程、(3)粗柔機に入れ、熱風で揉みながら乾かす粗柔工程、(4)葉に力を加えて、水分の均一をはかりながら揉む揉捻工程、(5)葉に熱と力とを加えて形を整えながら乾かす精揉工程、(6)葉を薄く広げて、熱風を当てて乾燥させる乾燥工程、(7)荒茶をふるいで分けるか切断して形を整える選別工程、(8)葉をさらに乾燥させて独自の香りや味を引き出す乾燥工程、(9)仕上がった葉を計量して茶箱や袋に詰め込む包装工程等からなる公知の製茶方法によって製造することができる。
他の飲食用組成物としては、例えば、お茶飲料、青汁、料理用食材、果実酒等が挙げられ、これらの飲食用組成物についても上記イチジク品種を原料として公知の製造方法で製造することができる。
(Eating and drinking composition)
Examples of the composition for eating and drinking according to the present invention include tea leaves. The tea leaves are (1) a steaming process in which steam is heated in a short time by steaming the leaves of the above-described fig cultivar, (2) a cooling process in which the surface of the tea leaves is cooled while removing moisture, and (3) crude soft Put into the machine and dry with hot air and dry, (4) Applying force to the leaves and twisting while keeping moisture even, (5) Applying heat and force to the leaves and drying while adjusting the shape (6) A drying process in which the leaves are spread thinly and dried by applying hot air. (7) A sorting process in which the crude tea is separated or cut to prepare a shape. (8) The leaves are further dried. It can be produced by a known tea-making method comprising a drying step that draws out the unique aroma and taste, and (9) a packaging step that measures the finished leaves and packs them into a tea box or bag.
Examples of other food and beverage compositions include tea beverages, green juice, food ingredients for cooking, fruit wine, etc., and these food and beverage compositions are also produced by the known production methods using the above-described fig varieties as raw materials. Can do.
(薬用組成物)
本発明に係る薬用組成物としては、例えば、生薬及びその抽出物が挙げられる。生薬は、上記イチジク品種の果実や葉等を乾燥させて、小片、小塊に切断または破砕、もしくは粉末に粉砕するなどして、公知の製造方法によって製造することができる。
(Medicinal composition)
Examples of the medicinal composition according to the present invention include herbal medicines and extracts thereof. The herbal medicine can be produced by a known production method by drying the fruit or leaf of the above-described fig variety and cutting or crushing it into small pieces or small chunks or crushing it into powder.
生薬の抽出物とは、生薬に適当な浸出剤を加えて浸出した液、または浸出液を濃縮した液をいい、具体的には「エキス」及び「チンキ」等を挙げることができる。浸出剤としては、例えば、水、エタノール、あるいは水とエタノールとの混合液等を挙げることができる。なお、抽出物の製造方法は公知の方法(例えば、日本薬局方記載の方法)を用いて良い。 The herbal medicine extract refers to a liquid leached by adding a suitable leaching agent to the herbal medicine, or a liquid obtained by concentrating the leaching liquid, and specifically includes "extract" and "tincture". Examples of the leaching agent include water, ethanol, or a mixed solution of water and ethanol. In addition, the manufacturing method of an extract may use a well-known method (For example, the method of Japanese Pharmacopoeia).
また、「エキス」を乾燥したものも上記抽出物に含まれ、これを通例「乾燥エキス」という。乾燥エキスの製造方法は公知の方法を用いて良い。一般に、生薬は基原が同一であれば、いずれの形態であっても同様の効果を得ることができる。 In addition, a product obtained by drying the “extract” is also included in the above extract, which is generally referred to as “dry extract”. A known method may be used as a method for producing the dried extract. In general, the same effect can be obtained in any form as long as the crude drug has the same base.
本発明に係る薬用組成物は、経口または非経口的に投与することができるが、経口的に投与することが好ましい。経口的に投与するための製剤(経口投与製剤)の剤形としては、エキス剤、エリキシル剤、シロップ剤、チンキ剤、リモナーデ剤等の液剤とカプセル剤、顆粒剤、丸剤、散剤、錠剤等の固形のものとを挙げることができる。本発明に係る薬用組成物を含む製剤は、公知の製剤技術により種々の剤形に製剤化することができ、製剤中には適当な製剤添加物を加えることができる。製剤添加物の具体例としては、賦形剤、結合剤、崩壊剤、懸濁化剤、防腐剤、抗酸化剤、矯味剤等を挙げることができる。製剤添加物は、製剤の投与量において人体等の生体にとって無害である必要があり、また有効成分の効果を妨げない必要がある。 The medicinal composition according to the present invention can be administered orally or parenterally, but is preferably administered orally. The dosage form of the preparation for oral administration (oral administration preparation) includes liquids and capsules such as extract, elixir, syrup, tincture, and limonade, granules, pills, powders, tablets, etc. Can be mentioned. The preparation containing the medicinal composition according to the present invention can be formulated into various dosage forms by known preparation techniques, and appropriate preparation additives can be added to the preparation. Specific examples of formulation additives include excipients, binders, disintegrants, suspending agents, preservatives, antioxidants, and corrigents. The formulation additive must be harmless to a living body such as a human body in the dosage of the formulation, and must not interfere with the effect of the active ingredient.
例えば、賦形剤としては、乳糖、コーンスターチ、結晶セルロース等が挙げられる。結合剤としては、アラビアゴム末、デキストリン、カルボキシメチルセルロース、ヒドロキシプロピルセルロース、ポリビニルアルコール等が挙げられる。崩壊剤としては、コーンスターチ、カルボキシメチルセルロース、カルボキシメチルセルロースカルシウム、クロスポピドン等が挙げられる。懸濁化剤としては、アルギン酸ナトリウム、ポリビニルピロリドン等が挙げられる。防腐剤としては、パラオキシ安息香酸エチル、パラオキシ安息香酸ブチル等が挙げられる。抗酸化剤としては、アスコルビン酸、トコフェロール等が挙げられる。矯味剤としては、白糖、ハチミツ、アスパルテーム、ステビア、グリチルリチン酸ニカリウム等が挙げられる。 For example, examples of the excipient include lactose, corn starch, and crystalline cellulose. Examples of the binder include gum arabic powder, dextrin, carboxymethyl cellulose, hydroxypropyl cellulose, polyvinyl alcohol and the like. Examples of the disintegrant include corn starch, carboxymethyl cellulose, carboxymethyl cellulose calcium, and crospovidone. Examples of the suspending agent include sodium alginate and polyvinyl pyrrolidone. Examples of the preservative include ethyl paraoxybenzoate and butyl paraoxybenzoate. Examples of the antioxidant include ascorbic acid and tocopherol. Examples of the corrigent include sucrose, honey, aspartame, stevia, and dipotassium glycyrrhizinate.
〔その他の実施形態〕
上記飲食用組成物及び薬用組成物の他に、フロクマリン類及びフロクマリン関連配糖体を含まないイチジク品種を原料として製造可能な組成物としては、例えば化粧用組成物、入浴剤用組成物、又は繊維を染色する染色用組成物等が挙げられる。
[Other Embodiments]
In addition to the above-mentioned eating and drinking composition and medicinal composition, as a composition that can be produced using fig varieties that do not contain furocoumarins and furocoumarin-related glycosides as raw materials, for example, a cosmetic composition, a composition for bathing agents, or Examples thereof include a dyeing composition for dyeing fibers.
〔抽出溶媒の検討〕
イチジクの葉からフロクマリン類及びフロクマリン関連配糖体の抽出するための抽出溶媒について検討した。
(実験方法)
1.葉の採取
(1)「プレコス・ロンデ・ド・ボルドー」種のイチジク樹より葉を採取した。
(2)採取した葉をおよそ2センチ角に刻み、直ちに冷凍保存した。
[Examination of extraction solvent]
The extraction solvents for extracting furocoumarins and furocoumarin-related glycosides from fig leaves were investigated.
(experimental method)
1. Collection of leaves (1) Leaves were collected from the fig tree of the “Precos Ronde de Bordeaux” species.
(2) The collected leaves were cut into approximately 2 cm squares and immediately stored frozen.
2−1.第1抽出方法
(1)冷凍状態の葉に対して9倍量(重量比)の水を加え、ミキサーで破砕した。
(2)懸濁液をガーゼで濾過し、次に遠心(500g×5分間)して上清を得た。
(3)適宜希釈し、ポアサイズ0.45μmのメンブランフィルターで濾過して分析用試料を得た。
2-1. First Extraction Method (1) Nine times the amount (weight ratio) of water was added to the frozen leaves and crushed with a mixer.
(2) The suspension was filtered with gauze and then centrifuged (500 g × 5 minutes) to obtain a supernatant.
(3) The sample was appropriately diluted and filtered through a membrane filter having a pore size of 0.45 μm to obtain a sample for analysis.
2−2.第2抽出方法
(1)凍結乾燥した葉を粉砕し、その0.2gを三角フラスコに入れ、30mLの抽出溶媒を加えた。抽出溶媒は水1重量部に対して有機溶媒類(メタノール、エタノール、プロパノール、アセトン)3重量部を混合したものを用いた。
(2)室温で3時間、毎分120回転の円運動で振とうしながら抽出した。
(3)毎分12000回転で10分間遠心し、上清を回収した。
(4)残渣に抽出溶媒を10mL加えて撹拌し、再び毎分12000回転で10分間遠心し、上清を回収した。
(5)上記4の操作をもう一度繰り返した。
(6)回収した上清を合わせて50mLに定容した。
(7)適宜水で希釈し、ポアサイズ0.45μmのメンブランフィルターで濾過して分析用試料を得た。
2-2. Second Extraction Method (1) Lyophilized leaves were pulverized, 0.2 g thereof was placed in an Erlenmeyer flask, and 30 mL of extraction solvent was added. The extraction solvent used was a mixture of 3 parts by weight of organic solvents (methanol, ethanol, propanol, acetone) with 1 part by weight of water.
(2) Extraction was performed while shaking with a circular motion of 120 revolutions per minute for 3 hours at room temperature.
(3) Centrifugation was performed at 12,000 rpm for 10 minutes, and the supernatant was collected.
(4) 10 mL of the extraction solvent was added to the residue and stirred, and centrifuged again at 12,000 rpm for 10 minutes to recover the supernatant.
(5) The above operation 4 was repeated once more.
(6) The collected supernatants were combined and made up to a volume of 50 mL.
(7) The sample for analysis was obtained by appropriately diluting with water and filtering through a membrane filter having a pore size of 0.45 μm.
2−3.第3抽出方法
上記第2抽出方法と同様の方法で行った。ただし、抽出溶媒には、水1重量部に対してメタノール1重量部を混合したもの、水1重量部に対してメタノール3重量部を混合したもの、メタノール及び0.1%の塩酸を添加したメタノールを用いた。
2-3. 3rd extraction method It carried out by the method similar to the said 2nd extraction method. However, to the extraction solvent, 1 part by weight of methanol mixed with 1 part by weight of water, 3 parts by weight of methanol mixed with 1 part by weight of water, methanol and 0.1% hydrochloric acid were added. Methanol was used.
3.分析方法
(1)上記第1〜3抽出方法で得られたそれぞれの分析用試料10μL(マイクロリットル)を高速液体クロマトグラフィー(HPLC)装置に注入して検出・定量した。
(2)HPLCの分析条件は以下の通りとした。
(a)カラム:Phenomenex社のAQUA C18、粒子径5μm、内径4.6mm×長さ250mm
(b)移動相A:2%酢酸
(c)移動相B:0.5%酢酸とアセトニトリルを1:1の割合で混合したもの
(d)移動相の流速:毎分1mL
(e)移動相グラジエント:分析時間に応じて、移動相Bの比率を以下の通りに変化させた。分析開始時:10%、20分後:24%、40分後:30%、60分後:55%、75分後:100%、83分後まで:100%、85分後:10%、90分後(分析終了)まで:10%。
(f)カラム温度:30℃
(g)成分の検出:吸光度検出器により波長250nmの吸光度を測定した。
(h)各成分の溶出時間:IPG:29〜30分付近、mIPG:31分付近、プソラレン:69〜70分付近、ベルガプテン:75分付近のピークとして検出される。
3. Analysis Method (1) 10 μL (microliter) of each analytical sample obtained by the above first to third extraction methods was injected into a high performance liquid chromatography (HPLC) apparatus for detection and quantification.
(2) HPLC analysis conditions were as follows.
(A) Column: Phenomenex AQUA C18,
(B) Mobile phase A: 2% acetic acid (c) Mobile phase B: 0.5% acetic acid and acetonitrile mixed at a ratio of 1: 1 (d) Mobile phase flow rate: 1 mL per minute
(E) Mobile phase gradient: The ratio of mobile phase B was changed as follows according to the analysis time. Analysis start time: 10%, 20 minutes later: 24%, 40 minutes later: 30%, 60 minutes later: 55%, 75 minutes later: 100%, until 83 minutes later: 100%, 85 minutes later: 10%, Until 90 minutes (end of analysis): 10%.
(F) Column temperature: 30 ° C
(G) Detection of component: Absorbance at a wavelength of 250 nm was measured with an absorbance detector.
(H) Elution time of each component: IPG: Detected as a peak at around 29-30 minutes, mIPG: around 31 minutes, psoralen: around 69-70 minutes, bergapten: around 75 minutes.
(実験結果)
第1抽出方法で得られたイチジク葉の水抽出液のHPLCクロマトグラムを図1に示すと共に、プソラレン、ベルガプテン、IPG、mIPGの各成分のピーク面積を以下の表1に示す。
(Experimental result)
The HPLC chromatogram of the aqueous extract of fig leaf obtained by the first extraction method is shown in FIG. 1, and the peak areas of each component of psoralen, bergapten, IPG, and mIPG are shown in Table 1 below.
図1及び表1に示すように、抽出溶媒を水とした場合では、プソラレンやベルガプテンは抽出されているが、IPGやmIPGがほとんど抽出されていない事が分かる。水抽出液にIPGやmIPGがほとんど含まれていなかった原因としては、(a)当該成分の抽出効率が極めて低い、あるいは(b)酵素が活性を保っていてそれにより分解された、事などが考えられる。 As shown in FIG. 1 and Table 1, when water is used as the extraction solvent, psoralen and bergapten are extracted, but it is understood that IPG and mIPG are hardly extracted. The reason why IPG and mIPG were hardly contained in the water extract was that (a) the extraction efficiency of the component was extremely low, or (b) the enzyme maintained its activity and was decomposed by it. Conceivable.
第2抽出方法で得られた4つの分析用試料、即ち、水1重量部とメタノール3重量部との混合液によるイチジク葉の抽出液(水+メタノール)、水1重量部とエタノール3重量部との混合液によるイチジク葉の抽出液(水+エタノール)、水1重量部とプロパノール3重量部との混合液によるイチジク葉の抽出液(水+プロパノール)、及び水1重量部とアセトン3重量部との混合液によるイチジク葉の抽出液(水+アセトン)におけるプソラレン、ベルガプテン、IPG、mIPGの各成分のピーク面積を以下の表2に示す。表2に示すように、いずれの抽出溶媒でもIPG、mIPGはほとんど抽出されなかった。 Four analytical samples obtained by the second extraction method, ie, fig leaf extract (water + methanol) in a mixture of 1 part by weight of water and 3 parts by weight of methanol, 1 part by weight of water and 3 parts by weight of ethanol Fig leaf extract (water + ethanol) in a mixed solution with Fig, fig leaf extract (water + propanol) in a mixture of 1 part by weight of water and 3 parts by weight of propanol, 1 part by weight of water and 3 parts by weight of acetone Table 2 below shows the peak areas of each component of psoralen, bergapten, IPG, and mIPG in the extract of fig leaf (water + acetone) by the mixed solution with the part. As shown in Table 2, IPG and mIPG were hardly extracted with any extraction solvent.
第3抽出方法で得られた4つの分析用試料、即ち、水1重量部とメタノール1重量部との混合液によるイチジク葉の抽出液(水1重量部+メタノール1重量部)、水1重量部とメタノール3重量部との混合液によるイチジク葉の抽出液(水1重量部+メタノール3重量部)、メタノールによるイチジク葉の抽出液(メタノール)、0.1%塩酸添加メタノールによるイチジク葉の抽出液(0.1%塩酸添加メタノール)におけるプソラレン、ベルガプテン、IPG、mIPGの各成分のピーク面積を以下の表3に示す。尚、0.1%塩酸添加メタノール抽出液に関する分析用試料のクロマトグラムを図2に示す。 Four analytical samples obtained by the third extraction method, that is, fig leaf extract (1 part by weight of water + 1 part by weight of methanol) and 1 part by weight of water using a mixture of 1 part by weight of water and 1 part by weight of methanol. Fig leaf extract (1 part by weight water + 3 parts by weight methanol), fig leaf extract (methanol) with methanol and 3 parts by weight methanol, fig leaf extract with methanol with 0.1% hydrochloric acid Table 3 below shows the peak areas of each component of psoralen, bergapten, IPG, and mIPG in the extract (0.1% hydrochloric acid-added methanol). In addition, the chromatogram of the sample for analysis regarding a 0.1% hydrochloric acid addition methanol extract is shown in FIG.
表3に示すように、水を含んだ溶媒では、メタノール比率が高いほどプソラレンとベルガプテンの抽出は良好となったが、IPGとmIPGはほとんど抽出されなかった。メタノール100%ではこの関係が逆転し、IPGとmIPGは非常によく抽出されたが、プソラレンとベルガプテンの抽出は激減した。メタノール100%に微量の塩酸を添加すると、IPGとmIPGの抽出は少し向上した。 As shown in Table 3, in the solvent containing water, the higher the methanol ratio, the better the extraction of psoralen and bergapten, but almost no IPG and mIPG were extracted. At 100% methanol, this relationship was reversed and IPG and mIPG were extracted very well, but the extraction of psoralen and bergapten was drastically reduced. When a small amount of hydrochloric acid was added to 100% methanol, the extraction of IPG and mIPG was slightly improved.
以上より、抽出溶媒を水及び0.1%塩酸添加メタノールとして、種々のイチジク品種について抽出試験を行うこととした。 From the above, extraction tests were conducted on various fig varieties using water and methanol with 0.1% hydrochloric acid as the extraction solvent.
〔水によるイチジク葉の抽出・分析試験〕
40品種のイチジク(「桝井ドーフィン」、「蓬莱柿」、「ヌアール・ド・カロン」、「ホワイト・イスキア」、「ネグローネ」、「ブランスウィック」、「ブルジャソット・グリス」、「テマリイチジク」、「ポルトガロ」、「ビオレ・ソリエス」、「ブラウン・ターキー」、「シュガー」、「アーテナ」、「セレスト」、「ホワイト・ゼノア」、「ポー・デュール」、「カリフォルニア・ブラック」、「フィグ・ド・マルセイユ」、「カドタ」、「ネグロ・ラーゴ」、「プレコス・ロンデ・ド・ボルドー」、「グリース・セント・ジャン」、「グリーズ・ビール」、「アイーダ」、「ミッション」、「グリスト・ジーン」、「グット・ドール」、「ベローネ」、「早生ドーフィン」、「ロンデ・ド・ボルドー」、「ダルマティー」、「アーチペル」、「リサ」、「ショート・ブリッジ」、「デザート・クイーン」、「サンピエトロ」、「サルタン」、「パスティエ」、「グリース・ド・タラスコン」、「ビオレ・ドーフィン」)のそれぞれの葉に含まれる成分を水で抽出して、高速液体クロマトグラフィー(HPLC)によって分析した。
[Extraction and analysis of fig leaf with water]
40 varieties of figs ("Sakurai Dauphin", "Sakai", "Nouard de Karon", "White Ischia", "Negrone", "Brunswick", "Burjasotto Gris", "Temari Figs", "Temari Figs" Portogaro, Biore Solies, Brown Turkey, Sugar, Artena, Celeste, White Zenoa, Pau Dur, California Black, Fig de Do Marseille, Cadota, Negro Lago, Precos Ronde de Bordeaux, Grease St Jean, Greez Beer, Aida, Mission, Grist Jean , "Gut Dole", "Bellone", "Early Dorfine", "Ronde de Bordeaux", "Dalmaty", "A Chipel, Lisa, Short Bridge, Desert Queen, St. Peter, Sultan, Pastier, Grease de Tarascon, Biore Dauphin) The components contained in were extracted with water and analyzed by high performance liquid chromatography (HPLC).
(実験方法)
(1)上記各品種のイチジク樹より新梢中央付近の葉を採取して冷凍保存した。
(2)冷凍状態の葉に対して9倍量(重量比)の水を加え、ミキサーで破砕した。
(3)懸濁液をガーゼで濾過し、次に遠心(500g×5分間)して得られた上澄みを、ポアサイズ0.45μmのメンブランフィルターで濾過して分析用試料(40試料)を得た。
(4)各分析用試料をHPLC装置で分析した。分析条件を以下に示す。
(a)カラム:Phenomenex社のAQUA C18、粒子径5μm、内径4.6mm×長さ250mm
(b)移動相A:2%酢酸
(c)移動相B:0.5%酢酸とアセトニトリルを1:1の割合で混合したもの
(d)移動相の流速:毎分1mL
(e)移動相グラジエント:分析時間に応じて、移動相Bの比率を以下の通りに変化させた。分析開始時:10%、20分後:24%、40分後:30%、60分後:55%、75分後:100%、83分後まで:100%、85分後:10%、90分後(分析終了)まで:10%。
(f)カラム温度:30℃
(g)成分の検出:吸光度検出器により波長250nmの吸光度を測定した。
(h)各成分の溶出時間:それぞれIPG:29〜30分付近、mIPG:31分付近、プソラレン:69〜70分付近、ベルガプテン:75分付近のピークとして検出される。
(experimental method)
(1) Leaves near the center of the new tree were collected from the fig trees of the above varieties and stored frozen.
(2) Nine times the amount (by weight) of water was added to the frozen leaves and crushed with a mixer.
(3) The suspension was filtered through gauze, and then the supernatant obtained by centrifugation (500 g × 5 minutes) was filtered through a membrane filter having a pore size of 0.45 μm to obtain a sample for analysis (40 samples). .
(4) Each analytical sample was analyzed with an HPLC apparatus. The analysis conditions are shown below.
(A) Column: Phenomenex AQUA C18,
(B) Mobile phase A: 2% acetic acid (c) Mobile phase B: 0.5% acetic acid and acetonitrile mixed at a ratio of 1: 1 (d) Mobile phase flow rate: 1 mL per minute
(E) Mobile phase gradient: The ratio of mobile phase B was changed as follows according to the analysis time. Analysis start time: 10%, 20 minutes later: 24%, 40 minutes later: 30%, 60 minutes later: 55%, 75 minutes later: 100%, until 83 minutes later: 100%, 85 minutes later: 10%, Until 90 minutes (end of analysis): 10%.
(F) Column temperature: 30 ° C
(G) Detection of component: Absorbance at a wavelength of 250 nm was measured with an absorbance detector.
(H) Elution time of each component: Detected as peaks at IPG: around 29 to 30 minutes, mIPG: around 31 minutes, psoralen: around 69-70 minutes, and bergapten: around 75 minutes, respectively.
(実験結果)
水ではフロクマリン関連配糖体である、IPGおよびmIPGはほとんど抽出されなかった。
(Experimental result)
In water, IPG and mIPG, which are furocoumarin-related glycosides, were hardly extracted.
また、40品種中、「グリース・ド・タラスコン」及び「ビオレ・ドーフィン」の2品種を除く38品種が、プソラレンおよびベルガプテンの両方を含んでいた。尚、HPLCクロマトグラムについては、日本国内で果実の収穫や茶葉等の製造のために経済栽培されている桝井ドーフィン(図3)及び蓬莱柿(図4)のクロマトグラムと、フロクマリン類(プソラレンおよびベルガプテン)を含まなかったグリース・ド・タラスコン(図5)及びビオレ・ドーフィン(図6)のクロマトグラムについてのみ示しており、残りの品種のクロマトグラムについては省略した。 Of the 40 varieties, 38 varieties excluding 2 varieties “Grease de Tarascon” and “Biore Dauphin” contained both psoralen and bergapten. As for HPLC chromatograms, the chromatograms of Sakurai Dofin (Fig. 3) and Koji (Fig. 4), which are economically cultivated in Japan for the production of fruits and tea leaves, etc., and furocoumarins (psoralen and Only the chromatograms of Grease de Tarascon (FIG. 5) and Biore Dauphin (FIG. 6) that did not contain bergapten were shown, and the remaining chromatograms were omitted.
〔0.1%塩酸添加メタノールによるイチジク葉の抽出・分析試験〕
上記40品種のイチジクのそれぞれの葉に含まれる成分を0.1%塩酸添加メタノールで抽出して、液体クロマトグラフ質量分析(LC−MS)によって分析した。
[Extraction and analysis of fig leaf with 0.1% hydrochloric acid-added methanol]
Components contained in the leaves of each of the 40 varieties of figs were extracted with 0.1% hydrochloric acid-added methanol and analyzed by liquid chromatography mass spectrometry (LC-MS).
(実験方法)
(1)上記各品種のイチジク樹より新梢中央付近の葉を採取して冷凍保存した。
(2)冷凍状態の葉を破砕して、25倍量(重量比)の溶媒(0.1%の塩酸を添加したメタノール)を加えた。
(3)時々撹拌しながら、室温で4時間置いて成分を抽出した。
(4)懸濁液を濾紙で濾過し、次にポアサイズ0.45μmのメンブランフィルターで濾過して分析用試料(40試料)を得た。
(5)分析用試料をLC−MS装置で分析した。分析条件を以下に示す。
(a)カラム:Phenomenex社のAQUA C18、粒子径5μm、内径4.6mm×長さ250mm
(b)移動相A:2%酢酸
(c)移動相B:0.5%酢酸とアセトニトリルを1:1の割合で混合したもの
(d)移動相の流速:毎分1mL
(e)移動相グラジエント:分析時間に応じて、移動相Bの比率を以下の通りに変化させた。分析開始時:10%、20分後:24%、40分後:30%、60分後:55%、75分後:100%、83分後まで:100%、85分後:10%、90分後(分析終了)まで:10%。
(f)カラム温度:30℃
(g)液体クロマトグラフ:吸光度検出器により波長250nmの吸光度を測定した。
(h)マススペクトル:質量分析計により以下の測定条件で成分イオンのm/z値を測定した。条件1:イオン化法:ESI(エレクトロスプレー法)、測定質量範囲:50〜1000m/z、フラグメンター電圧:150V、キャピラリー電圧:3500V、ネブライザーガス:N2(60psi)、乾燥ガス:N2(12L/min、350℃)、測定イオン:負イオン。条件2:イオン化法:APCI(大気圧化学イオン化法)、測定質量範囲:50〜1000m/z、フラグメンター電圧:100V、キャピラリー電圧:3000V、コロナ電流:4A、ネブライザーガス:N2(60psi)、乾燥ガス:N2(4L/min,350℃)、気化温度:350℃、測定イオン:正イオン。
(i)ピーク成分の同定:プソラレン、ベルガプテンは保持時間が標準物質のデータと一致することで同定した。
(j)各成分の溶出時間:それぞれIPG:29〜30分付近、mIPG:31分付近、プソラレン:69〜70分付近、ベルガプテン:75分付近のピークとして検出される。
(experimental method)
(1) Leaves near the center of the new tree were collected from the fig trees of the above varieties and stored frozen.
(2) Frozen leaves were crushed and a 25-fold amount (weight ratio) of solvent (methanol added with 0.1% hydrochloric acid) was added.
(3) The ingredients were extracted at room temperature for 4 hours with occasional stirring.
(4) The suspension was filtered through filter paper, and then filtered through a membrane filter having a pore size of 0.45 μm to obtain a sample for analysis (40 samples).
(5) The analytical sample was analyzed with an LC-MS apparatus. The analysis conditions are shown below.
(A) Column: Phenomenex AQUA C18,
(B) Mobile phase A: 2% acetic acid (c) Mobile phase B: 0.5% acetic acid and acetonitrile mixed at a ratio of 1: 1 (d) Mobile phase flow rate: 1 mL per minute
(E) Mobile phase gradient: The ratio of mobile phase B was changed as follows according to the analysis time. Analysis start time: 10%, 20 minutes later: 24%, 40 minutes later: 30%, 60 minutes later: 55%, 75 minutes later: 100%, until 83 minutes later: 100%, 85 minutes later: 10%, Until 90 minutes (end of analysis): 10%.
(F) Column temperature: 30 ° C
(G) Liquid chromatograph: Absorbance at a wavelength of 250 nm was measured with an absorbance detector.
(H) Mass spectrum: m / z values of component ions were measured with a mass spectrometer under the following measurement conditions. Condition 1: Ionization method: ESI (electrospray method), measurement mass range: 50 to 1000 m / z, fragmentor voltage: 150 V, capillary voltage: 3500 V, nebulizer gas: N 2 (60 psi), dry gas: N 2 (12 L / Min, 350 ° C.), measurement ion: negative ion. Condition 2: ionization method: APCI (atmospheric pressure chemical ionization method), measurement mass range: 50 to 1000 m / z, fragmentor voltage: 100 V, capillary voltage: 3000 V, corona current: 4 A, nebulizer gas: N 2 (60 psi), Dry gas: N 2 (4 L / min, 350 ° C.), vaporization temperature: 350 ° C., measurement ions: positive ions.
(I) Identification of peak components: Psoralen and bergapten were identified by the retention time agreeing with the data of the standard substance.
(J) Elution time of each component: Detected as peaks around IPG: 29 to 30 minutes, mIPG: around 31 minutes, psoralen: around 69 to 70 minutes, and bergapten: around 75 minutes, respectively.
(実験結果)
40品種中、「グリース・ド・タラスコン」及び「ビオレ・ドーフィン」の2品種を除く38品種が、IPGおよびmIPGの両方を含んでいた。尚、液体クロマトグラムについては、日本国内で茶葉等の製造のために経済栽培されている桝井ドーフィン(図7)及び蓬莱柿(図8)のクロマトグラムと、フロクマリン関連配糖体(IPG及びmIPG)を含まなかったグリース・ド・タラスコン(図9)及びビオレ・ドーフィン(図10)のクロマトグラムについてのみ示しており、残りの品種のクロマトグラムについては省略した。
(Experimental result)
Of the 40 varieties, 38 varieties except for 2 varieties of “Grease de Tarascon” and “Biore Dauphin” contained both IPG and mIPG. As for liquid chromatograms, the chromatograms of Sakurai Dofin (Fig. 7) and Koji (Fig. 8), which are economically cultivated in Japan for the production of tea leaves, etc., and furocoumarin-related glycosides (IPG and miPG) Only the chromatograms of Grease de Tarascon (FIG. 9) and Biore Dauphin (FIG. 10) that did not contain) were shown, and the chromatograms of the remaining varieties were omitted.
図9及び図10に示すように、「グリース・ド・タラスコン」及び「ビオレ・ドーフィン」のそれぞれの液体クロマトグラムにおいて、29分付近(29.808分)及び30分付近(30.173分)にIPGと思われるごく小さなピークが検出されたが、mIPGは検出されなかった。 As shown in FIGS. 9 and 10, in the liquid chromatograms of “Grease de Tarascon” and “Biore Dauphin”, around 29 minutes (29.808 minutes) and around 30 minutes (30.173 minutes) A very small peak that was considered to be IPG was detected, but mIPG was not detected.
質量分析計によって「グリース・ド・タラスコン」及び「ビオレ・ドーフィン」のそれぞれの上記極小ピークに含まれるイオンのm/zを調べたところ、図12及び図13に示すように、IPGが存在することを示す365m/zのイオン(図11参照)は明確に検出されなかった。従って、これらの極小ピークはIPG以外の夾雑物によるものと考えられる。 When m / z of ions contained in the above-mentioned minimum peaks of “Grease de Tarascon” and “Biore Dauphin” was examined by a mass spectrometer, there was IPG as shown in FIGS. An ion of 365 m / z indicating that (see FIG. 11) was not clearly detected. Therefore, these minimum peaks are considered to be due to impurities other than IPG.
以上より、「グリース・ド・タラスコン」と「ビオレ・ドーフィン」の2品種には、プソラレン、ベルガプテン、IPGおよびmIPGは含まれていないことが分かった。 From the above, it was found that the two varieties “Grease de Tarascon” and “Biore Dauphin” do not contain psoralen, bergapten, IPG and mIPG.
本発明の飲食用組成物及び薬用組成物は、光による皮膚疾患の発症や、薬物の副作用を増大させる等の健康被害をもたらす虞のない、お茶飲料、青汁、料理用食材、果実酒、生薬等として利用することができる。 The composition for eating and drinking according to the present invention and the medicinal composition are tea beverages, green juices, cooking ingredients, fruit liquors, which have no risk of causing health problems such as the onset of skin diseases caused by light and increased side effects of drugs, It can be used as a crude drug.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009223187A JP5560445B2 (en) | 2009-09-28 | 2009-09-28 | Eating and drinking composition and medicinal composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009223187A JP5560445B2 (en) | 2009-09-28 | 2009-09-28 | Eating and drinking composition and medicinal composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011067180A true JP2011067180A (en) | 2011-04-07 |
JP5560445B2 JP5560445B2 (en) | 2014-07-30 |
Family
ID=44013168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009223187A Active JP5560445B2 (en) | 2009-09-28 | 2009-09-28 | Eating and drinking composition and medicinal composition |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5560445B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018526347A (en) * | 2015-08-03 | 2018-09-13 | エルヴェエムアッシュ ルシェルシュ | Peelable cosmetic composition comprising candied citrus fruit pieces |
-
2009
- 2009-09-28 JP JP2009223187A patent/JP5560445B2/en active Active
Non-Patent Citations (1)
Title |
---|
JPN6013003151; 高橋徹 外3名: '「イチジク葉の抗酸化能とその関与成分について」' 東洋食品工業短大・東洋食品研究所 研究報告書 Vol.27, 200903, p.21-27 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018526347A (en) * | 2015-08-03 | 2018-09-13 | エルヴェエムアッシュ ルシェルシュ | Peelable cosmetic composition comprising candied citrus fruit pieces |
Also Published As
Publication number | Publication date |
---|---|
JP5560445B2 (en) | 2014-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5885153B2 (en) | Manufacturing method of processed ginger | |
KR102413705B1 (en) | Composition for improving liver function comprising Dendropanax morbifera extract | |
US11786839B2 (en) | Eutectic extract formation and purification | |
Rodrigues et al. | Subcritical water extraction and microwave-assisted extraction applied for the recovery of bioactive components from Chaya (Cnidoscolus aconitifolius Mill.) | |
JP6640392B2 (en) | Obesity control composition | |
MX2008012065A (en) | Extracts and methods comprising green tea species. | |
CN106132425B (en) | Composition containing citrus seed extract, food, drug, and method for producing composition containing citrus seed extract | |
JP2010209051A (en) | Fat absorption inhibitor | |
TW201043144A (en) | A method for producing a nutraceutical composition and the nutraceutical produced by the method | |
JP2006045212A (en) | Oral composition containing specific quinic acid derivative | |
JP2008056572A (en) | Water-soluble composition containing gingerol, method for producing water-soluble composition containing gingerol, and food, drink, cosmetic and medicine containing water-soluble composition containing gingerol | |
KR101617590B1 (en) | Antiobesity Food Composition Comprising Extract of Aronia, Acaiberry and Stevia | |
KR101834745B1 (en) | A manufacturing method of functional powder comprising abundant rutin ingredient | |
KR101404286B1 (en) | Method for preparing the extract fortified with chalcones from by-product of Angelica keiskei juice | |
KR102012872B1 (en) | High concentrate for beverage containing black raspberry, plantaginis asiatica l., schizandra chinensis, lycii fructus and torilis japonica decandolle and the high concentrate for beverage prepared from the same | |
CN109200082A (en) | A method of extracting from emblic, there is antioxidant activity to have Substance simultaneously | |
KR100872588B1 (en) | A composition comprising an extract of Ailanthus altissima having antioxidative effect | |
JP2007055951A (en) | Body fat reducing agent | |
JP2006006318A (en) | Taste-modifying agent | |
KR20120106218A (en) | Manufacturing method of treated puffing and fermentation red ginseng concentrate | |
JP5560445B2 (en) | Eating and drinking composition and medicinal composition | |
CN108042661B (en) | White tea extract rich in dihydromyricetin and application thereof in preparing medical health products | |
JP4537024B2 (en) | Inflammatory disease preventive / therapeutic agent | |
KR102604237B1 (en) | Composition for enhancing the bioavailability of fat-soluble vitamins | |
KR20100130020A (en) | A composition comprising novel black ginseng without tumor promoting agents such as benzopyran and the extract thereof obtained by novel process |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120724 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130122 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130131 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130530 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130829 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140516 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5560445 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |